Magnesium oxide and Pexidartinib Hydrochloride
Determining the interaction of Magnesium oxide and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: magnesium oxide
Brand name: MagGel, Phillips' Cramp-free, Uro-Mag, Mag-200, Mag-Ox 400, UroMag, Mag-Oxide, Magnesium Oxide 400, MAGnesium-Oxide, Maox, Uro-Mag
Synonyms: Magnesium Oxide
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Magnesium oxide-Pfizerpen
- Magnesium oxide-Pharaon Tea
- Magnesium oxide-Pharmorubicin Pfs
- Magnesium oxide-Phazyme
- Magnesium oxide-Phazyme Liquid Gas Relief, Maximum Strength
- Magnesium oxide-Phena-Plus
- Pexidartinib Hydrochloride-Magnesium Oxide 400
- Pexidartinib Hydrochloride-Magnesium salicylate
- Pexidartinib Hydrochloride-Magnesium sulfate
- Pexidartinib Hydrochloride-Magnesium Sulfate Granules (Epsom Salt)
- Pexidartinib Hydrochloride-Magnesium Sulfate in Dextrose Injection
- Pexidartinib Hydrochloride-Magnesium sulfate injection